<DOC>
	<DOCNO>NCT01546571</DOCNO>
	<brief_summary>The purpose study determine safe well POL-103A work prevent relapse melanoma patient undergone surgery .</brief_summary>
	<brief_title>Study Melanoma Vaccine Stage IIb , IIc , III Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm Stage IIb , IIc , III melanoma Surgical resection within 90 day first dose Persons positive sentinel node must complete lymphadenectomy ECOG performance status 0 1 Any prior melanoma treatment surgery regional irradiation Diagnosis noncutaneous melanoma melanoma unknown primary origin Use biologic response modifier within 60 day first dose Subjects history malignancy within past 5 year ( exception )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>